NYSE: $MRK A Significant Milestone for Ulcerative Colitis Treatment Merck recently announced encouraging top-line results from its Phase 2b clinical trial evaluating tulisokibart (MK-7240), an investigational TL1A inhibitor. The study focused on patients suffering from moderate to severe ulcerative colitis, a chronic condition that significantly impacts quality of life. Meeting Key Clinical Goals The study…